MRK vs VRDN
Merck & Co. vs Viridian Therapeutics, Inc. — AI-powered side-by-side comparison
VS
VRDN
Viridian Therapeutics, Inc.
64
Buy
| Metric | MRK | VRDN |
|---|
| AI Score |
70
|
64
|
| Price |
$130.34
|
$23.00
|
| P/E Ratio |
103.53×
|
-6.28×
|
| ROE |
34.7%
|
-47.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
99.4%
|
| Debt / Equity |
1.29×
|
0.37×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
74.5
|
| Beta |
0.207
|
0.94
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus VRDN.
MRK leads by 6 points.
MRK scores 70/100 (Buy) versus VRDN at 64/100 (Buy).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
VRDN Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 23220.3% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.1x prices in significant intangible value — Value
- ROE of only -61.4% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical